ADT in prostate cancer: Should docetaxel be added?
While combining docetaxel with androgen deprivation therapy (ADT) is known to improve survival for advanced prostate cancer, its role in the setting of adjuvant treatment given after radical radiotherapy plus ADT for the treatment of intermediate- and high-risk prostate cancer was proven otherwise — both in terms of biochemical disease-free survival (BDFS) and quality of life (QoL), according to the SPCG*-13 trial presented at the 2020 Genitourinary Cancer Symposium (GUCS).
